Related Experiment Video
Updated: May 11, 2026

Isolation of Primary Human Colon Tumor Cells from Surgical Tissues and Culturing Them Directly on Soft Elastic Substrates for Traction Cytometry
Published on: June 4, 2015
Engineered T cells and macrophages: two arms to seize solid tumors
Luigi Russo1, Ilaria De Martino1, Matteo Marchetti1
1Istituto Italiano di Tecnologia - IIT, Largo Barsanti e Matteucci 53, Naples, Italy.
Abstract:
Following the breakthroughs of CAR T cells in the treatment of several hematological malignancies, clinical trials based on genetically modified immune cells are exponentially increasing. Redirecting T cell cytotoxicity against solid tumors via CARs, however, encountered several barriers that require the engineering of additional functions to improve safety, migration, efficacy, and persistence in solid tumors. Complementary strategies tried to harness macrophage properties such as cancer cell phagocytosis, cytokine release, and antigen presentation to induce broader antitumorigenic immune response. While providing a comprehensive overview on the latest technologies in the cell-based immunotherapy realm, we propose that engineering synthetic interplay between immune cells will be the next breakthrough to drive safer and more effective living therapeutics.
Insights
Genetically modified immune cells, like CAR T-cells, show promise for treating blood cancers. Engineering new functions and combining cell types may overcome challenges for solid tumor immunotherapy.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Chimeric antigen receptor (CAR) T-cell therapy has shown success in hematological malignancies.
- Significant barriers hinder CAR T-cell efficacy against solid tumors, necessitating enhanced functionalities for safety, migration, and persistence.
- Macrophages offer complementary antitumor properties, including phagocytosis and antigen presentation, for a broader immune response.
Purpose of the Study:
- To provide a comprehensive overview of current cell-based immunotherapy technologies.
- To propose synthetic interplay between immune cells as a future breakthrough for improved cancer treatment.
- To highlight strategies for overcoming solid tumor immunotherapy challenges.
Main Methods:
- Review of recent advancements in genetically modified immune cell therapies.
- Analysis of strategies for engineering immune cells, including T cells and macrophages.
- Exploration of synthetic biology approaches for cell-cell communication in immunotherapy.
Main Results:
- CAR T-cell therapy faces challenges in solid tumors, requiring additional engineered functions.
- Macrophages possess properties that can augment antitumor immune responses.
- Current research focuses on enhancing immune cell capabilities for broader therapeutic applications.
Conclusions:
- Engineering synthetic interplay between different immune cells is a promising next step in cell-based immunotherapy.
- This approach aims to develop safer and more effective living therapeutics for cancer treatment.
- Overcoming solid tumor barriers requires innovative strategies beyond traditional CAR T-cell therapy.
More Related Videos
Related Concept Videos
Cell-mediated Immune Responses
The Tumor Microenvironment
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy

